Post by figglebird on Sept 17, 2018 12:56:07 GMT -5
Is the first subsidiary of a publicily held company(UNITED THERAPUTICS). That means that along with profitability and shareholder's value the charter of LUNG BIO TECH PBC also carries with it a cause to carry on business for the public good... now you might think all pharma would fit in this catagory, but, officially, it does not... From what I see, LUNG BIOTECH is the first... SO why is this important or not to mnkd?
Lung Biotech is responsible in part for all inhalation research/ medications such as TYVASO as a subsidiary of UTHR and has played a major role with SAMUMED'S phase studies that were announced today in terms of systic fibrosis... They are obviously the pulmonary brain/center of UTHR - Samused I read somewhere has a 12b dollar valuation as a private company which based on their research is interesting and potentially miniscule if they sucseed.
Anyhow, obviously, mnkd is a pulmonary focused pharma with not just a new deal on tyvaso but a research proposition that exceeds pah - this would possibly touch on samumed's molecules, who knows?
It's the public benefit part of lung bio tech that I am truly curious about - not just bc they are the first one in the us to ever be a subsidiary of any public company - but also, because of their role within that company and its similarities with respect to mnkds...
Perhaps more details that do/don't add up - but being as this is the way forward - and hoping uthr's interest was not simply to take out a competitor, we'll see.
Lung Biotech is responsible in part for all inhalation research/ medications such as TYVASO as a subsidiary of UTHR and has played a major role with SAMUMED'S phase studies that were announced today in terms of systic fibrosis... They are obviously the pulmonary brain/center of UTHR - Samused I read somewhere has a 12b dollar valuation as a private company which based on their research is interesting and potentially miniscule if they sucseed.
Anyhow, obviously, mnkd is a pulmonary focused pharma with not just a new deal on tyvaso but a research proposition that exceeds pah - this would possibly touch on samumed's molecules, who knows?
It's the public benefit part of lung bio tech that I am truly curious about - not just bc they are the first one in the us to ever be a subsidiary of any public company - but also, because of their role within that company and its similarities with respect to mnkds...
Perhaps more details that do/don't add up - but being as this is the way forward - and hoping uthr's interest was not simply to take out a competitor, we'll see.
